NCT06617091 (IAVI C114) is a Phase 1 clinical trial of GRAdHIVNE1 Vaccine in HIV, sponsored by International AIDS Vaccine Initiative.

Who is sponsoring NCT06617091?

NCT06617091 is sponsored by International AIDS Vaccine Initiative.

What drugs are being tested in NCT06617091?

Interventions in NCT06617091: GRAdHIVNE1 Vaccine, Placebo.

Is NCT06617091 still recruiting?

NCT06617091 is currently recruiting now. Last updated 13 February 2026.

Last reviewed 2026-02-13 · How we verify

NCT06617091: IAVI C114

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and With HIV.

Recruiting now Phase 1 Last updated 13 February 2026

What this trial tests

Phase 1 trial testing GRAdHIVNE1 Vaccine in HIV in 120 participants. Currently enrolling.

Timeline

28 July 2025

Primary endpoint
31 March 2027

31 March 2027

Quick facts

Lead sponsor	International AIDS Vaccine Initiative
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	120
Start date	28 July 2025
Primary completion	31 March 2027
Estimated completion	31 March 2027
Sites	3 locations across Zimbabwe, South Africa

Drugs / interventions tested

GRAdHIVNE1 Vaccine — full drug profile →
Placebo

Conditions studied

HIV — all drugs for HIV →

Sponsor

International AIDS Vaccine Initiative — full company profile →

Who can join

Adults 18 to 50, any sex, with HIV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase 1 Randomized Double Blinded Placebo Controlled, Dose Ranging Trial, of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine (GRAdHIVNE1 Vaccine), Administered to Healthy Adults Living without HIV and Living with HIV, in Southern Africa

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in Immune-Based Approaches for the Cure of HIV Infection.
Wagner JA, Sandel DA, Deitchman AN, Rutishauser RL, et al · · 2026 · PMID 42068526 · DOI 10.1007/s40265-026-02311-3
Human immunodeficiency virus vaccines: Advances, challenges and future perspectives.
Varatharajan S, Krishnasai S, Girish C. · · 2026 · PMID 41884456 · DOI 10.5501/wjv.v15.i1.116055
Non-Clinical Safety of GRAd Vector-Based COVID-19 and HIV Vaccines Supports a Platform Regulatory Approach.
Paalangara R, Gohin S, Menard A, Amy C, et al · · 2026 · PMID 41746078 · DOI 10.3390/vaccines14020157

Verify or expand the search:

Other recruiting trials for HIV

Currently open trials in the same condition.

NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting

Other International AIDS Vaccine Initiative trials

Trials by the same sponsor.

NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT06272812 — A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic R · Phase 2 · recruiting
NCT06449196 — Mosaic HIV-1 Envelope Trimer Immunogens Administered to People Living with HIV (PLWH) in Africa · EARLY_PHASE1 · withdrawn
NCT05724472 — Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health · Phase 1 · completed
NCT05414786 — A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06617091 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by International AIDS Vaccine Initiative
Last refreshed: 13 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06617091.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing